# Amgen Inc. (AMGN) has underperformed the broader market over the past year.

*biotech · news · 2026-04-30 · Barchart*

## Key points

- AMGN shares outperformed the Invesco Pharmaceuticals ETF YTD, despite lagging it over the past year.
- AMGN’s Q4 adjusted EPS of $5.29 and $9.9 billion revenue both exceeded Wall Street forecasts.
- AMGN’s analyst consensus has become less bullish, with fewer 'Strong Buy' ratings than three months ago.
- Canaccord Genuity recently initiated AMGN at 'Hold' with a $366 price target, implying 8.3% upside.

**Companies:** Amgen Inc.
**Countries:** United States

[Read the full story on Barchart](https://www.barchart.com/story/news/1619983/what-are-wall-street-analysts-target-price-for-amgen-stock)

---

Canonical: https://newsio.io/n/593881a5-c8eb-4ada-8675-14e40b314b78/amgen-inc-amgn-has-underperformed-the-broader-market-over-the-past-year-amgn-has
Summarized by Newsio from Barchart. https://newsio.io/how-it-works